Epilepsy

A recently published review reinforces ketogenic diet therapies as a clinically relevant option for epilepsy, particularly in pediatric and metabolic populations, while underscoring the need for more rigorous evidence to guide their optimal use.

New pharmacokinetic data presented at AAN 2026 show that adolescents with focal epilepsy achieve cenobamate exposures comparable to adults, supporting simplified fixed-dose strategies and informing future pediatric development.

A national survey presented at AAN 2026 revealed significant gaps between patients with epilepsy and clinicians in seizure expectations, treatment decisions, and communication around risks like SUDEP.

Edith Graham, MD, assistant professor of neurology at Northwestern Feinberg School of Medicine, discussed diagnostic challenges and induction therapy outcomes in primary CNS vasculitis.

Phase 3 EPIC trial design highlights NRTX-1001 cell therapy as a potential single-administration approach to achieving durable seizure reduction in drug-resistant MTLE.

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Neurology News Network for the week ending April 4, 2026. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending March 28, 2026. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 27, 2026.

Purple Day, observed each March 26, highlights the global impact of epilepsy while encouraging awareness, education, and open dialogue to reduce stigma and improve care for millions worldwide.

For Purple Day, M. Scott Perry, MD, a leader within the epilepsy community, shared thoughts and perspectives on the persistent gaps in epilepsy awareness, the hope for precision therapies, and the need for holistic care.

Adult epileptologist Danielle Becker, MD, MS, FAES, emphasized the need for improved education and structured, lifespan-based care to better address sex-specific risks in women with epilepsy.

The POLARIS program includes 3 ongoing phase 1/2 clinical trials investigating the efficacy and safety of investigational gene therapy EXT101 in patients with SCN1A postive Dravet syndrome.

In honor of Purple Day®, held on March 26, 2026, Mary Anne Meskis, chief executive officer of the Dravet Syndrome Foundation, highlighted ongoing efforts and future steps to raise awareness for rare epileptic disorders.

A post hoc analysis of the AMPA observational study found that adjunctive perampanel did not worsen daytime sleepiness over 12 months in patients with focal epilepsy while maintaining substantial seizure reduction.

Phase 3 data show azetukalner cuts monthly focal seizures in refractory epilepsy, offering a novel KV7 option ahead of 2026 FDA filing.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with AAN President Natalia Rost, MD, MPH. [LISTEN TIME: 16 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 6, 2026.

Neurologists Esther Bui, MD, and Angela O'Neal, MD, talked about the INSIGHT network, a collaborative global initiative designed to advance medical education in women’s neurology.

Praxis files FDA NDAs for ulixacaltamide and relutrigine, highlighting phase 3 tremor gains and major seizure cuts in rare DEEs.

Here's some of what is coming soon to NeurologyLive® this week.

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

Here's some of what is coming soon to NeurologyLive® this week.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.